Antibacterial effect of bismuth subsalicylate nanoparticles synthesized by laser ablation
Source abstract
Abstract
The antimicrobial properties of bismuth subsalicylate (BSS) nanoparticles against four opportunistic pathogens; E. coli, P. aeruginosa, S. aureus, and S. epidermidis were determined. BSS nanoparticles were synthesized by pulse laser ablation of a solid target in distilled water under different conditions. The nanoparticles were characterized using high-resolution transmission electron microscopy and absorption spectra and small angle X-ray scattering. The analysis shows that the colloids maintained the BSS structure and presented average particle size between 20 and 60 nm, while the concentration ranges from 95 to 195 mg/L. The antibacterial effect was reported as the inhibition ratio of the bacterial growth after 24 h and the cell viability was measured using the XTT assay. The results showed that the inhibition ratio of E. coli and S. epidermidis was dependant on the NPs size and/or concentration, meanwhile P. aeruginosa and S. aureus were more sensitive to the BSS nanoparticles independently of both the size and the concentration. In general, the BSS colloids with average particle size of 20 nm were the most effective, attaining inhibition ratios >80 %, similar or larger than those obtained with the antibiotic used as control. The results suggest that the BSS colloids could be used as effective antibacterial agents with potential applications in the medical area.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticles: synthesis and applications · Laser-Ablation Synthesis of Nanoparticles · TiO2 Photocatalysis and Solar Cells
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (60)
Show source-provided references
1. Adams CP, Walker KA, Obare SO, Docherty KM (2014) Size-dependent antimicrobial effects of novel palladium nanoparticles. PLoS ONE 9:e85981. doi: 10.1371/journal.pone.008598110.1371/journal.pone.0085981 ↗
2. Alipour M, Dorval C, Suntres ZE, Omri A (2011) Bismuth-ethanedithiol incorporated in a liposome-loaded tobramycin formulation modulates the alginate levels in mucoid Pseudomonas aeruginosa. J Pharm Pharmacol 63:999–1007. doi: 10.1111/j.2042-7158.2011.01304.x10.1111/j.2042-7158.2011.01304.x ↗
3. Andreasen JJ, Andersen LP (1987) In vitro susceptibility of Campylobacter pyloridis to cimetidine, sucralfate, bismuth and sixteen antibiotics. Acta Pathologica, Microbiologica, et Immunologica Scandinavica Sect B 95:147–149
4. Andrews PC, Deacon GB, Forsyth CM, Junk PC, Kumar I, Maguire M (2006) Towards a structural understanding of the anti-ulcer and anti-gastritis drug bismuth subsalicylate. Angew Chem 45:5638–5642. doi: 10.1002/anie.20060046910.1002/anie.200600469 ↗
5. Bera RK, Mandal SM, Raj CR (2014) Antimicrobial activity of fluorescent Ag nanoparticles. Lett Appl Microbiol 58:520–526. doi: 10.1111/lam.1222210.1111/lam.12222 ↗
6. Botequim D, Maia J, Lino MM, Lopes LM, Simoes PN, Ilharco LM, Ferreira L (2012) Nanoparticles and surfaces presenting antifungal, antibacterial and antiviral properties. Langmuir 28:7646–7656. doi: 10.1021/la300948n10.1021/la300948n ↗
7. Brogan AP, Verghese J, Widger WR, Kohn H (2005) Bismuth-dithiol inhibition of the Escherichia coli rho transcription termination factor. J Inorg Biochem 99:841–851. doi: 10.1016/j.jinorgbio.2004.12.01910.1016/j.jinorgbio.2004.12.019 ↗
8. Cornick NA, Silva M, Gorbach SL (1990) In vitro antibacterial activity of bismuth subsalicylate. Rev Infect Dis 12(Suppl 1):S9–S1010.1093/clinids/12.Supplement_1.S9 ↗
9. Cremet L et al (2015) Pathogenic potential of Escherichia coli clinical strains from orthopedic implant infections towards human osteoblastic cells. Pathog Dis. doi: 10.1093/femspd/ftv065
10. Delchier JC, Malfertheiner P, Thieroff-Ekerdt R (2014) Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Aliment Pharmacol Therap 40:171–177. doi: 10.1111/apt.1280810.1111/apt.12808 ↗
11. dos Santos CA et al (2014) Silver nanoparticles: therapeutical uses, toxicity, and safety issues. J Pharma Sci 103:1931–1944. doi: 10.1002/jps.2400110.1002/jps.24001 ↗
12. DuPont HL (1987) Bismuth subsalicylate in the treatment and prevention of diarrheal disease. Drug Intell Clin Pharm 21:687–69310.1177/106002808702100901 ↗
13. DuPont HL, Sullivan P, Pickering LK, Haynes G, Ackerman PB (1977) Symptomatic treatment of diarrhea with bismuth subsalicylate among students attending a Mexican university. Gastroenterology 73:715–71810.1016/S0016-5085(19)31771-8 ↗
14. Elmi F et al (2014) The use of antibacterial activity of ZnO nanoparticles in the treatment of municipal wastewater. Water Sci Technol 70:763–770. doi: 10.2166/wst.2014.23210.2166/wst.2014.232 ↗
15. Ericsson CD, Evans DG, DuPont HL, Evans DJ Jr, Pickering LK (1977) Bismuth subsalicylate inhibits activity of crude toxins of Escherichia coli and Vibrio cholerae. J Infect Dis 136:693–69610.1093/infdis/136.5.693 ↗
16. Fayaz AM, Balaji K, Girilal M, Yadav R, Kalaichelvan PT, Venketesan R (2010) Biogenic synthesis of silver nanoparticles and their synergistic effect with antibiotics: a study against gram-positive and Gram-negative bacteria. Nanomed-Nanotechnol 6:103–10910.1016/j.nano.2009.04.006 ↗
17. Feris K et al (2010) Electrostatic interactions affect nanoparticle-mediated toxicity to Gram-negative bacterium Pseudomonas aeruginosa PAO1. Langmuir 26:4429–443610.1021/la903491z ↗
18. Ge R, Chen Z, Zhou Q (2012) The actions of bismuth in the treatment of Helicobacter pylori infections: an update. Metallomics 4:239–243. doi: 10.1039/c2mt00180b10.1039/c2mt00180b ↗
19. Goodman CM, McCusker CD, Yilmaz T, Rotello VM (2004) Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjugate Chem 15:897–900. doi: 10.1021/bc049951i10.1021/bc049951i ↗
20. Hajipour MJ et al (2012) Antibacterial properties of nanoparticles. Trends Biotechnol 30:499–511. doi: 10.1016/j.tibtech.2012.06.00410.1016/j.tibtech.2012.06.004 ↗
21. Harris LG, Foster SJ, Richards RG (2002) An introduction to Staphylococcus aureus, and techniques for identifying and quantifying S. aureus adhesins in relation to adhesion to biomaterials: review. Eur Cell Mater 4:39–6010.22203/eCM.v004a04 ↗
22. Hernandez L, Vazquez B, Lopez-Bravo A, Parra J, Goni I, Gurruchaga M (2007) Acrylic bone cements with bismuth salicylate: behavior in simulated physiological conditions. J Biomed Mater Res, Part A 80:321–332. doi: 10.1002/jbm.a.3094710.1002/jbm.a.30947 ↗
23. Hernandez-Delgadillo R, Velasco-Arias D, Diaz D, Arevalo-Nino K, Garza-Enriquez M, De la Garza-Ramos MA, Cabral-Romero C (2012) Zerovalent bismuth nanoparticles inhibit Streptococcus mutans growth and formation of biofilm. Int J Nanomed 7:2109–2113. doi: 10.2147/IJN.S29854
24. Hernandez-Delgadillo R, Velasco-Arias D, Martinez-Sanmiguel JJ, Diaz D, Zumeta-Dube I, Arevalo-Nino K, Cabral-Romero C (2013) Bismuth oxide aqueous colloidal nanoparticles inhibit Candida albicans growth and biofilm formation. Int J Nanomed 8:1645–1652. doi: 10.2147/IJN.S38708
25. Huh AJ, Kwon YJ (2011) “Nanoantibiotics”: a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J Control Release 156:128–145. doi: 10.1016/j.jconrel.2011.07.00210.1016/j.jconrel.2011.07.002 ↗
26. Jiang W, Mashayekhi H, Xing BS (2009) Bacterial toxicity comparison between nano- and micro-scaled oxide particles. Environ Pollut 157:1619–162510.1016/j.envpol.2008.12.025 ↗
27. Khan SS, Mukherjee A, Chandrasekaran N (2011) Studies on interaction of colloidal silver nanoparticles (SNPs) with five different bacterial species. Colloid Surf B 87:129–13810.1016/j.colsurfb.2011.05.012 ↗
28. Kim EC, Lee BC, Chang HS, Lee W, Hong CU, Min KS (2008) Evaluation of the radiopacity and cytotoxicity of Portland cements containing bismuth oxide. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 105:e54–e57. doi: 10.1016/j.tripleo.2007.08.00110.1016/j.tripleo.2007.08.001 ↗
29. Kim SH, Tramontina VA, Papalexiou V, Luczsyzyn SM, De Lima AA, do Prado AM (2012) Bismuth subgallate as a topical haemostatic agent at the palatal wounds: a histologic study in dogs. Int J Oral Maxillofac Surg 41:239–243. doi: 10.1016/j.ijom.2011.12.00210.1016/j.ijom.2011.12.002 ↗
30. Lipovsky A, Gedanken A, Nitzan Y, Lubart R (2011) Enhanced inactivation of bacteria by metal-oxide nanoparticles combined with visible light irradiation. Lasers Surg Med 43:236–240. doi: 10.1002/lsm.2103310.1002/lsm.21033 ↗
31. Luo Y, Hossain M, Wang CM, Qiao Y, An JC, Ma LY, Su M (2013) Targeted nanoparticles for enhanced X-ray radiation killing of multidrug-resistant bacteria. Nanoscale 5:687–69410.1039/C2NR33154C ↗
32. Mahony DE, Woods A, Eelman MD, Burford N, Veldhuyzen van Zanten SJ (2005) Interaction of bismuth subsalicylate with fruit juices, ascorbic acid, and thiol-containing substrates to produce soluble bismuth products active against Clostridium difficile. Antimicrob Agents Chemother 49:431–433. doi: 10.1128/AAC.49.1.431-433.200510.1128/AAC.49.1.431-433.2005 ↗
33. Manhart MD (1990) In vitro antimicrobial activity of bismuth subsalicylate and other bismuth salts. Rev Infect Dis 12(Suppl 1):S11–S1510.1093/clinids/12.Supplement_1.S11 ↗
34. Markowska K, Grudniak AM, Wolska KI (2013) Silver nanoparticles as an alternative strategy against bacterial biofilms. Acta Biochim Pol 60:523–530
35. Mijnendonckx K, Leys N, Mahillon J, Silver S, Van Houdt R (2013) Antimicrobial silver: uses, toxicity and potential for resistance. Biometals 26:609–621. doi: 10.1007/s10534-013-9645-z10.1007/s10534-013-9645-z ↗
36. Morones JR, Elechiguerra JL, Camacho A, Holt K, Kouri JB, Ramirez JT, Yacaman MJ (2005) The bactericidal effect of silver nanoparticles. Nanotechnology 16:2346–235310.1088/0957-4484/16/10/059 ↗
37. Nazari P et al (2014) The antimicrobial effects and metabolomic footprinting of carboxyl-capped bismuth nanoparticles against Helicobacter pylori. Appl Biochem Biotechnol 172:570–579. doi: 10.1007/s12010-013-0571-x10.1007/s12010-013-0571-x ↗
38. Pacifico L, Osborn JF, Anania C, Vaira D, Olivero E, Chiesa C (2012) Review article: bismuth-based therapy for Helicobacter pylori eradication in children. Aliment Pharmacol Ther. doi: 10.1111/j.1365-2036.2012.05055.x
39. Palanikumar L, Ramasamy SN, Balachandran C (2014) Size-dependent antimicrobial response of zinc oxide nanoparticles. IET Nanobiotechnol 8:111–117. doi: 10.1049/iet-nbt.2012.000810.1049/iet-nbt.2012.0008 ↗
40. Pardo OA, Pardo Castello V (1952) The treatment of early syphilis with penicillin and bismuth subsalicylate; follow-up report. Am J Syph Gonorrhea Vener Dis 36:342–345
41. Purvis JE (1926) CV.: the absorption spectra of various derivatives of salicylic acid. J Chem Soc 48:775–77810.1039/JR9262900775 ↗
42. Purvis JE (1927) The absorption spectra of various alkaloids and their salicylates and of derivatives of salicylic acid. J Chem Soc:2715-271910.1039/JR9270002715 ↗
43. Riool M et al (2014) Staphylococcus epidermidis originating from titanium implants infects surrounding tissue and immune cells. Acta Biomater 10:5202–5212. doi: 10.1016/j.actbio.2014.08.01210.1016/j.actbio.2014.08.012 ↗
44. Rispoli F, Angelov A, Badia D, Kumar A, Seal S, Shah V (2010) Understanding the toxicity of aggregated zero valent copper nanoparticles against Escherichia coli. J Hazard Mater 180:212–216. doi: 10.1016/j.jhazmat.2010.04.01610.1016/j.jhazmat.2010.04.016 ↗
45. Roy A, Gauri SS, Bhattacharya M, Bhattacharya J (2013) Antimicrobial activity of CaO nanoparticles. J Biomed Nanotechnol 9:1570–157810.1166/jbn.2013.1681 ↗
46. Rybtke M, Hultqvist LD, Givskov M, Tolker-Nielsen T (2015) Pseudomonas aeruginosa biofilm infections: community structure, antimicrobial tolerance and immune response. J Mol Biol. doi: 10.1016/j.jmb.2015.08.016
47. Schaller M, Laude J, Bodewaldt H, Hamm G, Korting HC (2004) Toxicity and antimicrobial activity of a hydrocolloid dressing containing silver particles in an ex vivo model of cutaneous infection. Skin Pharmacol Physiol 17:31–36. doi: 10.1159/00007406010.1159/000074060 ↗
48. Serena T et al (2007) Bismuth subgallate/borneol (suile) is superior to bacitracin in the human forearm biopsy model for acute wound healing. Adv Skin Wound Care 20:485–492. doi: 10.1097/01.ASW.0000288208.85807.b810.1097/01.ASW.0000288208.85807.b8 ↗
49. Shaikh AR, Giridhar R, Yadav MR (2007) Bismuth-norfloxacin complex: synthesis, physicochemical and antimicrobial evaluation. Int J Pharm 332:24–30. doi: 10.1016/j.ijpharm.2006.11.03710.1016/j.ijpharm.2006.11.037 ↗
50. Slikkerveer A, de Wolff FA (1989) Pharmacokinetics and toxicity of bismuth compounds. Med Toxicol Advers Drug Exp 4:303–32310.1007/BF03259915 ↗
51. Sox TE, Olson CA (1989) Binding and killing of bacteria by bismuth subsalicylate. Antimicrob Agents Chemother 33:2075–208210.1128/AAC.33.12.2075 ↗
52. Steinhoff MC, Douglas RG Jr, Greenberg HB, Callahan DR (1980) Bismuth subsalicylate therapy of viral gastroenteritis. Gastroenterology 78:1495–149910.1016/S0016-5085(19)30507-4 ↗
53. Tillman LA, Drake FM, Dixon JS, Wood JR (1996) Review article: safety of bismuth in the treatment of gastrointestinal diseases. Aliment Pharmacol Therap 10:459–46710.1046/j.1365-2036.1996.22163000.x ↗
54. Tomita RJ, de Matos RA, Vallim MA, Courrol LC (2014) A simple and effective method to synthesize fluorescent nanoparticles using tryptophan and light and their lethal effect against bacteria. J Photochem Photobiol, B 140C:157–162. doi: 10.1016/j.jphotobiol.2014.07.01510.1016/j.jphotobiol.2014.07.015 ↗
55. Tramontina VA, Machado MA, Nogueira Filho Gda R, Kim SH, Vizzioli MR, Toledo S (2002) Effect of bismuth subgallate (local hemostatic agent) on wound healing in rats. Histol Histometric Find Braz Dent J 13:11–16
56. Tsuang YH, Sun JS, Huang YC, Lu CH, Chang WHS, Wang CC (2008) Studies of photokilling of bacteria using titanium dioxide nanoparticles. Artif Organs 32:167–17410.1111/j.1525-1594.2007.00530.x ↗
57. Wang ZP, Lee YH, Wu B, Horst A, Kang YS, Tang YJJ, Chen DR (2010) Anti-microbial activities of aerosolized transition metal oxide nanoparticles. Chemosphere 80:525–52910.1016/j.chemosphere.2010.04.047 ↗
58. Weir E, Lawlor A, Whelan A, Regan F (2008) The use of nanoparticles in anti-microbial materials and their characterization. Analyst 133:835–845. doi: 10.1039/b715532h10.1039/b715532h ↗
59. Yang G (2012) Laser ablation in liquids: principles and applications in the preparation of nanomaterials. Pan Stanford Publishing Pte Ltd, Boston10.1201/b11623 ↗
60. Zhang LL, Jiang YH, Ding YL, Povey M, York D (2007) Investigation into the antibacterial behaviour of suspensions of ZnO nanoparticles (ZnO nanofluids). J Nanopart Res 9:479–48910.1007/s11051-006-9150-1 ↗